Eisai Co., Ltd. (TYO:4523)
Japan · Delayed Price · Currency is JPY | Market Cap | 1.27T |
| Revenue (ttm) | 804.39B |
| Net Income (ttm) | 49.37B |
| Shares Out | 281.89M |
| EPS (ttm) | 175.06 |
| PE Ratio | 25.72 |
| Forward PE | 25.17 |
| Dividend | 160.00 (3.60%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 1,844,700 |
| Average Volume | 1,306,730 |
| Open | 4,442.00 |
| Previous Close | 4,441.00 |
| Day's Range | 4,425.00 - 4,503.00 |
| 52-Week Range | 3,463.00 - 5,349.00 |
| Beta | -0.27 |
| RSI | 45.78 |
| Earnings Date | Nov 5, 2025 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer’s disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for prim... [Read more]
Full Company ProfileFinancial Performance
In 2024, Eisai's revenue was 789.40 billion, an increase of 6.42% compared to the previous year's 741.75 billion. Earnings were 46.43 billion, an increase of 9.49%.
Financial StatementsNews
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript
Q2 2026 Eisai Co Ltd Earnings Presentation Transcript
Eisai Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Eisai reports H2 results
Eisai H1 Profit Rises
(RTTNews) - Eisai Co. reported that its first half profit attributable to owners of the parent was 24.63 billion yen, an increase of 13.5% from prior year. Basic earnings per share was 87.37 yen compa...
Full Year 2025 Eisai Co Ltd Earnings Presentation Transcript
Full Year 2025 Eisai Co Ltd Earnings Presentation Transcript
Merck (MRK) and Eisai Conclude Keytruda-Lenvima Trial for Liver Cancer
Merck (MRK) and Eisai Conclude Keytruda-Lenvima Trial for Liver Cancer
Merck and Eisai's treatment combination fails liver cancer trial
Merck, Eisai discontinue late-stage study for liver cancer therapy
Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy to treat a type of liver cancer, after interim results showed the treatment...
Merck (MRK) and Eisai Report Positive Results in Kidney Cancer Trial
Merck (MRK) and Eisai Report Positive Results in Kidney Cancer Trial
Merck Says WELIREG,LENVIMA Combination Therapy Meets PFS Goal In Phase 3 Kidney Cancer Trial
(RTTNews) - Merck & Co Inc. (MRK) and Eisai oCo. Ltd (ESALY.PK) on Tuesday said that the Phase 3 LITESPARK-011 trial evaluating Merck's WELIREG in combination with Eisai's LENVIMA met one of its prima...
Merck, Eisai combo meets key goal in advanced kidney cancer trial
Merck-Eisai's cancer drug combo meets one main goal in late-stage study
Merck and Eisai's experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage study, the drugmakers said on Tuesday.
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
TOKYO and CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Headquarters: Cambridge, Massachusetts , C...
Eisai Co., Ltd. (ESAIY) Special Call - Slideshow
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance dosing in ...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Eisai : LEQEMBI Approved In China For Monthly IV Maintenance Dosing In Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced that the National Medical Products Administration (NMPA) of China has approved LEQEMBI—a humanized monoclonal ...
Leqembi® approved for the treatment of early Alzheimer's disease in Australia
STOCKHOLM , Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi...
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO , Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd.
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data...